Luis Eduardo Rosa Zucca

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad et al. · The Lancet Oncology · 2019 · 383 citations · Full text

Era 223, Urology, Medicine +8

Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients

Flávia Gonçalves Fernandes, Henrique C.S. Silveira, João Neif Antonio Júnior et al. · International Journal of Molecular Sciences · 2021 · 32 citations · Full text

Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib

Luis Eduardo Rosa Zucca, Mariana Andozia Morini Matushita, Renato José da Silva Oliveira et al. · Urologic Oncology Seminars and Original Investigations · 2017 · 29 citations · Full text

AXL as a modulator of sunitinib response in glioblastoma cell lines

Olga Martinho, Luis Eduardo Rosa Zucca, Rui Manuel Reis · Experimental Cell Research · 2015 · 26 citations · Full text

ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)

Mitchell R. Smith, Chris Parker, Fred Saad et al. · Annals of Oncology · 2018 · 16 citations · Full text

Era 223, Urology, Oncology +6